neovascular glaucomas การใช้

Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage.
Currently, there are no high-quality controlled trials demonstrating a beneficial effect of anti-VEGF treatments in lowering IOP in people with neovascular glaucoma.
Many retina specialists have noted impressive results in the setting of CNV, proliferative diabetic retinopathy, neovascular glaucoma, diabetic macular edema, retinopathy of prematurity and macular edema secondary to retinal vein occlusions.
"' Neovascular glaucoma "', an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy ( PDR ) or central retinal vein occlusion ( CRVO ).
A Cochrane Review seeking to determine the effectiveness of anti-VEGF agents such as ranibizumab and bevacizumab on lowering intraocular pressure in patients with neovascular glaucoma was inconclusive, as more research is needed to compare anti-VEGF treatments with conventional treatments.